315 related articles for article (PubMed ID: 37046312)
1. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract][Full Text] [Related]
2. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer.
Sun R; Sun Y; Wu C; Liu Y; Zhou M; Dong Y; Du G; Luo H; Shi B; Jiang H; Li Z
Mol Ther; 2023 Nov; 31(11):3193-3209. PubMed ID: 37735875
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
[TBL] [Abstract][Full Text] [Related]
4. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH
PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287
[TBL] [Abstract][Full Text] [Related]
5. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.
Sun R; Luo H; Su J; Di S; Zhou M; Shi B; Sun Y; Du G; Zhang H; Jiang H; Li Z
Mol Ther; 2021 Jan; 29(1):60-74. PubMed ID: 33010818
[TBL] [Abstract][Full Text] [Related]
6. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract][Full Text] [Related]
7. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
[TBL] [Abstract][Full Text] [Related]
8. Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma.
Dai Z; Lin X; Wang X; Zou X; Yan Y; Wang R; Chen Y; Tasiheng Y; Ma M; Wang X; Cheng H; Yu X; Liu C
Cancer Immunol Immunother; 2024 Mar; 73(4):61. PubMed ID: 38430267
[TBL] [Abstract][Full Text] [Related]
9. Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma.
McKenna MK; Ozcan A; Brenner D; Watanabe N; Legendre M; Thomas DG; Ashwood C; Cummings RD; Bonifant C; Markovitz DM; Brenner MK
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653070
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma.
Dorst DN; Smeets EMM; Klein C; Frielink C; Geijs D; Trajkovic-Arsic M; Cheung PFY; Stommel MWJ; Gotthardt M; Siveke JT; Aarntzen EHJG; van Lith SAM
Mol Pharm; 2023 Aug; 20(8):4319-4330. PubMed ID: 37485886
[TBL] [Abstract][Full Text] [Related]
11. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
[TBL] [Abstract][Full Text] [Related]
12. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
13. Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment.
Lin Y; Li B; Yang X; Cai Q; Liu W; Tian M; Luo H; Yin W; Song Y; Shi Y; He R
Neoplasia; 2019 Dec; 21(12):1133-1142. PubMed ID: 31759251
[TBL] [Abstract][Full Text] [Related]
14. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma.
Kawase T; Yasui Y; Nishina S; Hara Y; Yanatori I; Tomiyama Y; Nakashima Y; Yoshida K; Kishi F; Nakamura M; Hino K
BMC Gastroenterol; 2015 Sep; 15():109. PubMed ID: 26330349
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity.
Akai M; Noma K; Kato T; Nishimura S; Matsumoto H; Kawasaki K; Kunitomo T; Kobayashi T; Nishiwaki N; Kashima H; Kikuchi S; Ohara T; Tazawa H; Choyke PL; Kobayashi H; Fujiwara T
Br J Cancer; 2024 Jun; 130(10):1647-1658. PubMed ID: 38555315
[TBL] [Abstract][Full Text] [Related]
17. IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models.
Shi H; Li A; Dai Z; Xue J; Zhao Q; Tian J; Song D; Wang H; Chen J; Zhang X; Zhou K; Wei H; Qin S
Front Immunol; 2023; 14():1165404. PubMed ID: 37564658
[TBL] [Abstract][Full Text] [Related]
18. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.
Das S; Valton J; Duchateau P; Poirot L
Front Immunol; 2023; 14():1172681. PubMed ID: 37251405
[TBL] [Abstract][Full Text] [Related]
19. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
20. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy.
Shahvali S; Rahiman N; Jaafari MR; Arabi L
Drug Deliv Transl Res; 2023 Jul; 13(7):2041-2056. PubMed ID: 36840906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]